How sCD13 May Affect MS and COVID-19 Inflammation

Credibility

Interest

Key Takeaway

A substance called sCD13 might make COVID-19 worse by causing too much inflammation in the body.

What They Found

Researchers found that a protein called sCD13 is released by certain cells when there is inflammation. In people with COVID-19, levels of sCD13 were higher, especially in those who were more seriously ill. This protein seems to help certain immune cells, called neutrophils, become more active and cause more inflammation. Think of sCD13 like a loud alarm that makes the body's defenses go into overdrive, sometimes causing more harm than good. The study also noted that sCD13 doesn't make blood cells clump together, which is good because that can lead to blockages in blood vessels.

Who Should Care and Why

This finding is important for people with multiple sclerosis (MS) because managing inflammation is key to feeling better. Just like a car engine can overheat if it works too hard, too much inflammation can make MS symptoms worse. Caregivers and healthcare providers should pay attention to these findings because they could help identify new treatments that keep inflammation in check. If doctors can target sCD13, it might lead to better ways to manage both COVID-19 and MS, especially for those who are more vulnerable. Understanding this link can help patients and caregivers make informed choices about treatments and lifestyle adjustments.

Important Considerations

The study focused on COVID-19, so we still need to see how these findings apply to MS and other conditions. It’s also important to remember that while sCD13 is linked to inflammation, it’s just one piece of a much bigger puzzle. More research is needed to fully understand how sCD13 affects MS symptoms and what this means for treatment options.

Categories:

Early Research MS Genetics MS Progression

Article Topics:

COVID-19Endothelial cellsImmunologyInfectious diseaseNeutrophilsThrombosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JCI insight often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News